Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.43 |
| ▸ | WNT1 | P04628 | 4/20 | 0.42 |
| ▸ | GSK3B | P49841 | 4/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | BACE1 | P56817 | 3/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | CLK3 | P49761 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1075019 | 0.91 | ALK (0.53) | ALDH1A1ALKWNT1GSK3BDYRK1A | |
| SCHEMBL13634041 | 0.89 | L3MBTL1 (0.41) | ALDH1A1ALKJAK2L3MBTL1MGLL | |
| SCHEMBL13634103 | 0.88 | ALK (0.41) | ALDH1A1ALKJAK2L3MBTL1 | |
| SCHEMBL13634042 | 0.88 | ALK (0.43) | ALKJAK2 | |
| SCHEMBL13633155 | 0.87 | ALK (0.40) | ALDH1A1ALKJAK2 | |
| Trifluoroacetic Acid SCHEMBL4361257 | 0.87 | ALK (0.49) | ALDH1A1ALKWNT1GSK3BDYRK1A | |
| SCHEMBL4361284 | 0.87 | ALK (0.51) | ALDH1A1ALKWNT1GSK3BDYRK1A | |
| SCHEMBL13632984 | 0.84 | ALK (0.44) | ALKJAK2 | |
| SCHEMBL13633000 | 0.84 | ALK (0.41) | ALKJAK2 | |
| SCHEMBL13632930 | 0.84 | ALDH1A1 (0.46) | ALDH1A1ALKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | ALDH1A1 2511/4885ALK 3/4885WNT1 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.